Assembly Biosciences (ASMB) stock meets Mark Minervini's Trend Template with a perfect technical rating, 397% from lows, and accelerating 298% revenue growth.
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved target plasma concentrations for antiviral efficacy.
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to 13,517.59. The S&P 500 also fell, dropping, 0.10% to 4,369.41.
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
U.S. stocks traded mostly higher midway through trading, with the Dow Jones falling gaining around 100 points on Tuesday. The Dow traded up 0.31% to 34,090.15 while the NASDAQ fell 0.05% to 13,560.52. The S&P 500 also rose, gaining, 0.25% to 4,384.43.
